
Ask a doctor about a prescription for LIDOCAINE KABI 20 mg/ml INJECTABLE SOLUTION
Package Leaflet: Information for the User
Lidocaine Kabi 20 mg/ml Solution for InjectionEFG
Lidocaine hydrochloride (as monohydrate)
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
Lidocaine Kabi is a local anesthetic. It is used to:
Do not use Lidocaine Kabi:
Warnings and precautions
Tell your doctor, pharmacist, or nurse before you start using Lidocaine Kabi:
Children
Lidocaine Kabi is not recommended for use in neonates (less than one month old).
Using Lidocaine Kabi with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
In particular, tell your doctor if you are taking any of the following medicines, as they may interact with Lidocaine Kabi:
If adrenaline (epinephrine) is to be added to your lidocaine injection, you should also tell your doctor if you have high blood pressure, lack of blood supply to the brain, an overactive thyroid gland, or if you are taking antidepressant medicines. If you are going to receive a strong anesthetic to put you to sleep, you should tell your doctor if you have already received a lidocaine injection containing adrenaline (epinephrine).
If you are already taking one of these medicines, talk to your doctor before using Lidocaine Kabi.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine.
Your doctor will only give you this medicine during pregnancy or breastfeeding if it is necessary.
Driving and using machines
Depending on where and how this medicine is used, it may affect your ability to drive or use machines. Your doctor will tell you if you can drive or use machines.
Do not drive or use machines if you are under the effects of Lidocaine Kabi.
Lidocaine Kabi 20 mg/ml solution for injection contains sodium
This medicine contains 32 mg (approximately 1.39 mmol) of sodium (the main component of table salt) per dose. This is equivalent to 1.6% of the maximum daily dietary intake of 2 mg of sodium recommended by the WHO for an adult.
Your doctor will decide the most suitable dose for you according to your age and physical circumstances, as well as the site of injection, the method used, and your response to the injection.
If you are given too much Lidocaine Kabi
Because this medicine will be given to you by a trained professional, it is unlikely that you will be given too much Lidocaine Kabi.
However, if you think you have been given too much, or if you start to feel dizzy or lightheaded, numbness or tingling in your lips or around your mouth, or ringing in your ears, you should tell the person giving you the injection immediately.
If you have any other questions about the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse immediately if you experience an allergic reaction, which includes:
Other possible side effects are:
Very common(may affect more than 1 in 10 people)
Common(may affect up to 1 in 10 people)
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Not known(cannot be estimated from the available data)
After spinal injection of Lidocaine Kabi, you should tell your doctor if you experience any of the following symptoms:
For patients who go home before the numbness or loss of sensation caused by a local anesthetic has worn off:
During the time you feel numbness in the injected area, serious injuries can occur without you realizing it. To avoid injuries, be careful until the anesthesia has worn off or sensation and touch have returned.
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly through the Medicines and Healthcare products Regulatory Agency (MHRA) Yellow Card Scheme at www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
This medicine does not require any special storage conditions.
After opening the ampoule, use immediately and discard the unused portion of the solution.
Do not use if the ampoule is damaged or broken.
If it is diluted in a sodium chloride 9 mg/ml (0.9%) solution or a glucose 50 mg/ml (5%) solution under strict aseptic conditions, the solution should also be used immediately.
However, if the diluted solution is not used immediately, it should not be stored for more than 12 hours under strict aseptic conditions below 25°C.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Lidocaine Kabi
Lidocaine Kabi 20 mg/ml solution for injection:
Each ml of solution for injection contains 20 mg of lidocaine hydrochloride (as monohydrate) corresponding to 16.22 mg of lidocaine.
Each 5 ml of solution for injection contains 100 mg of lidocaine hydrochloride.
Each 10 ml of solution for injection contains 200 mg of lidocaine hydrochloride.
Each 20 ml of solution for injection contains 400 mg of lidocaine hydrochloride.
Appearance of Lidocaine Kabi and pack contents
Lidocaine Kabi is a clear, colorless aqueous solution, practically free from visible particles.
Lidocaine Kabi is available in low-density polyethylene ampoules with a twist-off cap.
Pack sizes
Ampoules of 5 ml in packs of 5, 10, 20, 50, or 100.
Ampoules of 10 ml in packs of 5, 10, 20, 50, or 100.
Ampoules of 20 ml in packs of 5, 10, 20, 50, or 100.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer:
Marketing authorization holder
Fresenius Kabi España, S.A.U.
C/Marina 16-18
08005 Barcelona
Spain
Manufacturer
Labesfal – Laboratórios Almiro, S.A.
Zona Industrial do Lagedo
3465-157 - Santiago de Besteiros
Portugal
This medicine is authorized in the Member States of the European Economic Area under the following names:
Member State | Medicine name |
Belgium | Lidocaine Fresenius Kabi 10 mg/ml, 20 mg/ml oplossing voor injectie |
France | Lidocaïne Kabi 10 mg/ml, 20 mg/ml solution injectable |
Italy | Lidocaina Kabi |
Ireland | Lidocaine Hydrochloride 1%, 2% w/v solution for injection |
Poland | Lidocaine 1%, 2% Fresenius Kabi |
Portugal | Lidocaína Fresenius Kabi |
Romania | Lidocaina Fresenius Kabi 10mg/ml, 20mg/ml solutie injectabila |
Slovenia | Lidokain Kabi 10 mg/ml, 20 mg/ml raztopina za injiciranje |
Spain | Lidocaína Kabi 10 mg/ml, 20 mg/ml solución inyectable |
United Kingdom | Lidocaine Hydrochloride 1%, 2% w/v solution for injection |
This leaflet was last revised in:May 2018.
<------------------------------------------------------------------------------------------------------------------------>
This information is intended only for healthcare professionals:
Special precautions
Lidocaine Kabi solution for injection is not recommended for use in neonates. In this age group, the optimal serum concentration of lidocaine required to avoid toxicity, such as seizures and cardiac arrhythmias, is unknown.
Handling and compatibility
Lidocaine Kabi solution for injection may be diluted in sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solutions.
The diluted solution should be inspected visually and not used if it shows opalescence, visible particles, or precipitates.
If it is diluted in sodium chloride 9 mg/ml (0.9%) or glucose 50 mg/ml (5%) solutions under strict aseptic conditions, the solution should also be used within 12 hours.
Lidocaine is incompatible with solutions containing amphotericin B, sulfadiazine sodium, methohexital sodium, cefazolin sodium, phenytoin, glyceryl trinitrate, and other alkaline solutions. Therefore, it is not advisable to mix Lidocaine Kabi with other agents.
Drugs stable in acidic media, such as adrenaline hydrochloride, noradrenaline tartrate, or isoprenaline, may deteriorate after mixing with lidocaine hydrochloride, and lidocaine solutions may raise the pH above the maximum pH for their stability.
Disposal of waste
Any unused product or waste material should be disposed of in accordance with local requirements.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for LIDOCAINE KABI 20 mg/ml INJECTABLE SOLUTION – subject to medical assessment and local rules.